Stock 1795 LOTUS PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

End-of-day quote Taiwan S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
301 TWD +4.88% Intraday chart for Lotus Pharmaceutical Co., Ltd. +4.70% +10.66%
05-11 Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-26 Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lotus Pharmaceutical Co., Ltd. Announces Director Changes
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023
Lotus Pharmaceutical Co., Ltd. Announces Board Changes
Lotus Pharmaceutical Co., Ltd. Announces Tenure Expiration of the Remuneration Committee Members
Lotus Pharmaceutical Co., Ltd. Announces Change in Audit Committee Members
Lotus Pharmaceutical Co., Ltd. Announces Change of Directors
GNW-Adhoc: NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen Inc. kündigen Zusammenarbeit zur Entwicklung und Vermarktung von NRX-101 an
NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen Inc. annoncent leur collaboration pour le développement et la commercialisation du NRX-101
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1795 Stock
  4. News Lotus Pharmaceutical Co., Ltd.
  5. Other languages